How Are We Signing Into This Blog?

A week ago I sent Daniel Ha, founder and CEO of Disqus, an email asking him to pull some stats from this blog's comment service (which disqus powers). I wanted to know the breakdown of commenters for the previous two weeks and how they logged in to comment.

Here is the data:

TOTAL COMMENTS:

Facebook Connect: 44
Guest (anonymous): 125
Twitter Sign-in: 130
Disqus Profile: 888

TOTAL UNIQUE COMMENTERS:

Facebook Connect: 33 people (avg: 1.3 comments / person)
Twitter Sign-in: 78 people (avg: 1.6 comments / person)
Guest: 125 people (avg: 1.0 comments / person) 
Disqus Profile: 362 people (avg: 2.4 comments / person)

The dominance of the disqus profile should not be surprising since I've been using them for almost two years now and most of the frequent commenters on this blog have a disqus profile.

But the rise of Facebook Connect and Twitter Sign-in are impressive. I've had Facebook Connect for a few months and I've had Twitter Sign-in for the past month. In a short period of time, they have taken over guest logins and are generating significantly more engagement than a guest login.

My hope is that guest logins start to fall away. This blog will always support a guest login for commenting (and over the weekend guest logins got the ability to subscribe to a comment thread). But I feel that people who comment with a real profile are generally more thoughtful with their comments and it creates a stronger community.

I'm also pleased to see Twitter sign-in doing so well. I've tried commenting via Facebook Connect and Twitter sign-in and I think the latter is much simpler. So it's not totally surprising that it's doing a little better on this blog. Both are strong products and I expect when and if I do this query in a year from now, we'll see both Facebook Connect and Twitter sign-in with even more penetration than they have now.

I'm curious to hear all of your thoughts on the sign in process, the new options from Facebook and Twitter, and what more you'd like.

Reblog this post [with Zemanta]